KP Management’s Cardlytics CDLX Stock Holding History

KP Management’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2,500	Closed	-$230K	–	73
2023 Q4	$230K	Buy	+2,500	New	+$254K	0.1%	80

Other funds holding CDLX

CIP

CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

KGAMU

KPS Global Asset Management (UK) London, United Kingdom $619M AUM 27.68% 1-Year Est. Return

WPM

Worldly Partners Management Needham, Massachusetts $118M AUM 19.19% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

KP Management's CDLX Position: Q1 2024 in Review

KP Management sold out of Cardlytics (CDLX) in Q1 2024, closing a stake of 2,500 shares — an estimated $230K sold.

KP Management first reported a position in CDLX in Q4 2023 and held it in 1 quarter. The position peaked at $230K in Q4 2023. 144 funds tracked by Wall St. Rank hold CDLX as of Q1 2024.

KP Management reported no remaining Cardlytics position as of Q1 2024 after selling out during the quarter.
KP Management sold 2,500 Cardlytics shares in Q1 2024, an estimated $230K.
KP Management first reported a position in Cardlytics in Q4 2023 and held it in 1 quarter.
KP Management's Cardlytics position peaked at $230K in Q4 2023.
144 funds tracked by Wall St. Rank held Cardlytics as of Q1 2024.

Based on KP Management's 13F filing for Q1 2024, filed 19 Sep 2024.